Spring (Plus de 45 000 résultats)

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Acceptable. Item in acceptable condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc. Campbell, Dawn Edge (illustrateur).

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : New. Item is in 'like new' condition. Zurcher, Lauren (illustrateur).

Etat : Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc. Zurcher, Lauren (illustrateur).

Etat : Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Acceptable. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Etat : Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Paperback. Etat : Good. The Harry Potter series may be named after the Boy Who Lived, but if you want to know the story, keep your eyes fixed on Severus Snape. This hook-nosed, greasy-haired, grumpy character is one of J.K. Rowling's enduring gifts to English literature. He's the archetypal ill-tempered teacher: acerbic, yet horribly, deliciously funny. When he's in a scene, you can't take your eyes off him. Snape is always the story. - From the Introduction In this examination of J.K. Rowling's most enigmatic character, Lorrie Kim shows us how to sort through the illusions and lies to the man who dared to spy on Voldemort. In his final moments, he asks Harry, and the reader, to Look at me. This book does just that.…

Paperback. Etat : Good. Shows how to create chic characters by combining stylish clothes with great hairstyles, pretty facial features and appealing poses.

Hardback. Etat : Very Good. Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. His book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled.…